- FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis
- FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis
- FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
- FDA Approves Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
- FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis
- FDA Approves Eylea (aflibercept) Injection Prefilled Syringe
- FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults
- FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults
- FDA Approves Keytruda (pembrolizumab) for Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
- FDA Approves Nubeqa (darolutamide) for Men with Non-Metastatic Castration-Resistant Prostate Cancer
- FDA Approves Accrufer (ferric maltol) for the Treatment of Iron Deficiency in Adults
- FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia
- FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira
- FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
- Baxter Announces U.S FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion